Peptides as immune suppressant
Technology
APIM-peptides are synthetic cell-penetrating peptides that target DNA sliding clamps in both bacteria and mammalian cells. In stressed mammalian cells, they bind strongly to the modified eukaryote DNA sliding clamp, PCNA, and suppress immune responses, alter signaling and metabolism, and reduce cytokine release after toll-like receptor activation. APIM-peptides have minimal effect on unstressed cells.
Market
The global immunosuppressants market was valued at approximately $40 billion in 2024 and is projected to reach over $87 billion by 2030, with a compound annual growth rate (CAGR) of around 13-14%.
Uniqueness
APIM-peptides have a new target and a new mode of action as an immunosuppressant. The anti-cancer lead APIM-peptide showed no grade 3 or 4 toxicity in a Phase I clinical study in advanced cancer patients, i.e., no myelosuppression was detected.
Status
- 2nd generation APIM-peptides patent to be submitted early 2026.
- Seeking commercial partners.
